LRP5 and type 2 diabetes mellitus: The findings will clarify the regulation of the Wnt/LRP5/β-catenin signaling pathway by semaglutide, thereby establishing an experimental foundation for the effectiveness of GLP-1RA in patients with T2DM and osteoporosis.